Caliper Life Sciences snags CRi in $20M deal; Myriad acquires melanoma diagnostic tech;

 @FierceBiotech: J&J offers $2.3B in bid for Crucell shares. Article | Follow @FierceBiotech

 @JohnCFierce: Enter the bio-dragon. China taps biotech as one of seven industries that will grow at 20%+ rate for the next 10 years. News | Follow @JohnCFierce

> Caliper Life Sciences, a supplier to the drug research industry, has struck a deal to buy Cambridge Research & Instrumentation for about $20 million, including debt. Caliper will issue common stock valued at about $10.5 million, pay cash of approximately $7.5 million, and assume CRi indebtedness of approximately $2 million. "CRi's advanced platforms add an important new dimension of capability to our suite of next-generation life science tools, and positions Caliper to further address biomarker discovery and companion diagnostics solutions for personalized medicine development programs," said Kevin Hrusovsky, CEO of Caliper Life Sciences. Caliper release

> Myriad Genetics is buying diagnostic skin cancer technology from Melanoma Diagnostics. Story

> A business consultant and his relative pleaded guilty to insider trading charges related to the delayed trial of a new genetic test from Sequenom. Report

And Finally...California officials were forced to scramble in an effort to track down a drug used for executions. The worldwide search for sodium thiopental took more than two months. Story

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.